I was scrolling through the industry data on Friday afternoon when I saw the number: 18,410.

That's how many times Novo Nordisk's oral semaglutide tablet (Wegovy) was prescribed through its second week of availability in the United States. Two weeks. January 16, 2026. That's more than 1,300 prescriptions per day.

For context, when the injectable Wegovy launched, it took months to reach those weekly numbers. When Lilly's Zepbound (tirzepatide) came out, it had impressive uptake, but not like this. And yet here we are.

My first thought was the same one I suspect you had: "There goes the supply chain." Novo's manufacturing can't keep up. There will be shortages. Patients will get frustrated. Pharmacies will struggle to fill scripts.

But then I had a different thought, one I want to share with you because I think it changes how you should position your independent pharmacy right now.

The real story isn't the shortage. The real story is that GLP-1 therapy has reached a tipping point. It's mainstream. It's cash-pay. It's happening at scale. And independent pharmacies that understand this moment have a concrete opportunity to build a new revenue stream without being constrained by the PBM pressure that limits other medication categories.

Let me explain what I mean, and then show you the three things you need to do immediately to capture this opportunity.

The GLP-1 Market Has Fundamentally Changed

Two years ago, GLP-1s were a specialist play. Endocrinologists and their patients. Medicare coverage was sparse. Insurance barriers were significant. Most patients couldn't access them.

That was 2024. We're in 2026 now. Everything changed.

Novo Nordisk's oral tablet hit a market that was already primed. Injectable Wegovy had spent years being prescribed, but access barriers stayed high. Insurance coverage inconsistent. Patient out-of-pockets often $300 to $500 per month even with coverage.

Then the oral tablet launched. Same medication. Easier to take. And here's the key: Novo's direct-to-consumer marketing has convinced millions of Americans that they want this medication.

And here's what I mean by "cash-pay becomes mainstream": Many of those patients filling Wegovy prescriptions aren't going through their insurance. They're paying cash. They're going online, connecting with telehealth providers, filling prescriptions, and paying out of pocket.

Why? Because for many patients, the cash price ($300 to $400 per month through various discount programs) is actually cheaper than their insurance copay or deductible. Because insurance often still has prior auth requirements, step therapy, or coverage restrictions. Because the telehealth experience is fast, simple, and doesn't require dealing with their insurance.

This is the shift: GLP-1s went from "insurance game" to "consumer choice."

And that's where independent pharmacies can actually win. Because cash-pay patients aren't constrained by PBM reimbursement pressure. They're not subject to DIR fees. They don't care about your acquisition cost. They care about three things: Can you fill it? Will you counsel me? What's the price?

That's a different game than the insurance game. And we can win at that game.

The Three Pillars of Independent Pharmacy GLP-1 Success

Building a GLP-1 program at your pharmacy isn't about chasing volume. It's about building a defensible, profitable, patient-centered model. Here are the three pillars.

Pillar 1: Clinical Positioning Through Intensive Counseling

The first mistake most pharmacies make is treating GLP-1 prescriptions like any other script. Scan, count, label, bag. Done.

That's leaving money and patients on the table.

The pharmacies winning with GLP-1 are positioning themselves as the GLP-1 counseling destination. That's a specific choice.

Here's what it looks like:

Create a GLP-1 intake and counseling protocol.

When a patient brings in a Wegovy prescription for the first time, they don't just get filled. They get counseled. The pharmacist spends 15 to 20 minutes with them on:

• How the medication works and what to expect

• Common side effects (nausea, GI effects, appetite loss) and how to manage them

• Drug interactions specific to the patient

• Nutritional changes they should anticipate (they'll eat less, get full faster, need to be intentional about protein intake)

• Injection technique if it's the injectable formulation

• Frequency of refills and reorder timing

• What to monitor (response, side effects, tolerance)

This isn't casual conversation. This is clinical pharmacy. This is what "practicing at the top of your license" actually looks like.

Partner with a nutritionist or registered dietitian. This is not mandatory, but it's powerful. Patients on GLP-1s need guidance on nutrition because their appetite and eating patterns change dramatically. If you can offer "talk to our partner RD before you start" or even just reference materials, patients see your pharmacy as the comprehensive GLP-1 center.

Create patient education materials specific to GLP-1.

Most patient education is generic. Create specific materials for your pharmacy about Wegovy side effects, dietary adjustments, medication interactions, when to contact you, when to contact their prescriber. Patients will ask for them. They'll share them. This is brand building.

Track patient outcomes. This is where it gets interesting for reimbursement. When a patient on GLP-1 is also your diabetes patient or hypertension patient, you're seeing outcomes. Blood pressure improvements. Weight loss. Medication simplifications (some patients can reduce diabetes medications as they lose weight). Track this. It's the foundation for MTM reimbursement conversations.

Position GLP-1 counseling as a billable service for some patients.

Medicaid coverage of GLP-1s is increasing. When Medicaid patients fill GLP-1s, some states allow pharmacist-provided counseling or medication therapy management. You might be able to bill for this directly. Even if you can't bill, intensive counseling improves adherence, improves outcomes, and builds patient loyalty.

For cash-pay patients, you might offer "GLP-1 initiation counseling" as a $50 to $100 cash service. Some patients will pay for expert guidance.

The clinical positioning is what separates you from the chain pharmacy down the street. They'll fill the script. You'll manage the patient.

Pillar 2: Inventory and Sourcing Strategy for Shortage Reality

Here's the honest truth about GLP-1 supply: It's still constrained in many markets.

Novo Nordisk is ramping manufacturing. The injectable versions have been backordered or short consistently since launch. The oral tablet is new, so allocation is uncertain. And as demand increases (18,000 scripts inw just two weeks, remember), shortages are inevitable.

The pharmacies that handle this well are the ones with diversified sourcing.

Set up reorder alerts with your primary wholesaler. Know when Wegovy is in stock and when it's out. Set alerts at specific dollar amounts or quantities. Don't let it fall below a safety stock level without knowing.

Maintain a secondary wholesaler relationship specifically for GLP-1s. If your primary wholesaler is out, can you source from a secondary? Get the relationship established now, before you need it in an emergency.

Join a pharmacy group buying organization if you haven't already. GPOs negotiate better allocation from manufacturers during shortages. NCPA members get priority access to scarce inventory.

Leverage RxPost for GLP-1 sourcing. When your wholesalers are out and you have a patient waiting, RxPost connects you to other independent pharmacies who might have inventory. DSCSA-compliant, documented, immediate access. You're not over-ordering due to shortage anxiety. You're sourcing just-in-time from peers.

This is crucial: Don't overbuy GLP-1s out of fear of shortage. Yes, shortages will happen. But if you stock six months of inventory because you're worried about shortage, you're tying up massive capital on a medication that has consistency issues, might be subject to recall, and could have demand fluctuations. Stock conservatively. Have backup sourcing plans.

Implement inventory tracking for expiration risk. GLP-1s are expensive. If you buy a month's supply and it expires before you sell it, that's lost profit. Track expiration dates carefully. Know your patient demand pattern. Order accordingly.

Build relationships with GLP-1 prescribers in your market. Telehealth platforms, primary care clinics, weight loss centers, endocrinologists. When you have good relationships, they know to send patients to you. You're not finding inventory. Inventory finds you through referrals.

The sourcing strategy says: I'm not going to panic-buy. I'm going to have multiple pathways to get what my patients need.

Pillar 3: Cash-Pay Patient Experience That Meets E-Commerce Expectations

Here's something that took me a minute to understand: Patients buying GLP-1s cash are different from your traditional insurance patients.

They're used to buying online. They expect fast, simple transactions. They want to know the price upfront. They want delivery options. They don't want friction.

Your pharmacy probably doesn't feel like that experience. It feels like a traditional brick-and-mortar place where they come in, wait, and leave with a bag.

That's fine. That's your advantage. But you need to understand the expectation mismatch and bridge it.

Create a cash GLP-1 ordering pathway.

Some patients will want to come in. Others will want to call ahead, reserve their medication, pick up later. Some will want delivery. Some will want to pay online, come get it. Create options.

The bridge between "online DTC experience" and "local pharmacy" is simple: Tell them when you'll have it. Price it clearly. Make it easy to pay. Be fast.

Transparent pricing is non-negotiable.

When a patient calls asking about Wegovy cost, they should get a straight answer. Not "it depends on your insurance." Just: "Cash price is $X. We can fill this as soon as you have a prescription. Here's how to pay." This builds trust immediately..

Create online price transparency. Your website should state that you fill GLP-1 prescriptions and give a ballpark price range. Make it easy for patients to contact you.

Position yourself as the patient education and counseling alternative to DTC providers. Telehealth platforms are great for prescription convenience. You're great for clinical depth. When a patient is worried about side effects, when they want a full medication review, when they want professional guidance... that's where you win. Make that clear.

Track patient satisfaction. GLP-1 patients are health-conscious and quality-conscious. They'll leave reviews. They'll recommend you. Make the experience excellent. Track feedback. Improve.

The cash-pay patient experience differs from insurance patients. Acknowledge it. Adapt to it. You'll win.

Making This Concrete: Immediate Implementation

You don't need a huge GLP-1 program to start winning. You need to start.

This week:

Pull your prescription data from the last 90 days. How many GLP-1 scripts have you filled? Semaglutide, tirzepatide, any GLP-1 medications. Get the number. That's your baseline.

This month:

Create a one-page GLP-1 counseling checklist. Common side effects, drug interactions, dietary changes, when to contact the pharmacy. Print it. Have it ready to give to your next GLP-1 patient.

Call one endocrinologist or weight loss clinic in your area. Introduce yourself. Tell them you're focusing on GLP-1 patient support. Ask if they refer to pharmacies. Get on their radar.

Check your wholesaler's GLP-1 availability. Set up reorder alerts. Know what's in stock and what's not.

By end of quarter:

Join a clinical resource network focused on GLP-1 therapy. There are several, including resources from the American Association of Clinical Endocrinologists and platform-specific training. Your pharmacist should be able to speak competently about GLP-1 therapy.

Establish a secondary sourcing pathway for GLP-1s. That could be a secondary wholesaler, a pharmacy group, or RxPost.

Build relationships with three prescribers in your market (telehealth platforms, clinics, or weight loss centers).

Why This Matters for Independent Pharmacy

Here's the deeper point I want to make: GLP-1 therapy is one of the few areas where independent pharmacies have a structural advantage right now.

We don't have as much PBM pressure because many patients are paying cash. We can focus on clinical excellence instead of fighting reimbursement. We can build relationships with local prescribers instead of depending on corporate allocation. We can provide personalized counseling that chains struggle to match.

The chains are filling GLP-1 scripts. They're doing volume. But they're not positioning themselves as GLP-1 specialists. They're not doing intensive counseling. They're not differentiating.

That's the opportunity. That's where we win.

Novo Nordisk's 18,000 prescriptions in one week isn't a threat. It's a signal. It says the market is ready. Patients want this. There's cash to be made and patients to be served.

But only if we position ourselves differently than we have for the last 20 years of commodity-driven pharmacy.

Take Action This Week

Identify your GLP-1 volume. How many scripts in the last 90 days? If zero, you're behind. If 10 to 20, you're early. If 50+, you're already in the game.

Create your GLP-1 counseling checklist. Write down five things every patient should know before starting GLP-1. Print it. Use it.

Check your wholesaler's stock. Is Wegovy in stock? What's the allocation? How often is it available?

Find one local prescriber. Could be an endocrinologist, weight loss clinic, telehealth platform partner, or primary care clinic. Find someone. Get their contact info. Schedule coffee.

Next Steps and Resources

The entrepreneurial pharm tech mindset sees opportunity where others see disruption. GLP-1 is one of those opportunities. The market is real. The patient demand is real. The profit potential is real.

And independent pharmacies are positioned better than anyone to own the GLP-1 counseling and support space locally. We just have to choose to build it.

Subscribe to The Entrepreneurial Pharm Tech newsletter for monthly updates on GLP-1 clinical insights, sourcing strategies, and how other independent pharmacies are building their programs.

Follow RxPost on social (Facebook, Instagram, LinkedIn) for stories from independent pharmacies managing supply chain challenges and building new patient programs.

Join your state pharmacy association and local chapters. Connect with other pharmacies building GLP-1 programs. Share what's working.

Connect with us on WhatsApp for questions about sourcing strategy, DSME coordination, or clinical partnerships.

The GLP-1 moment is here. Eighteen thousand prescriptions in the first week. That's the market. The question isn't whether GLP-1s are big. The question is: Will you position your pharmacy to lead in your market?